Annual report pursuant to Section 13 and 15(d)

Nature of Business (Details Narrative)

v3.21.1
Nature of Business (Details Narrative) - USD ($)
1 Months Ended
Feb. 25, 2021
Nov. 17, 2020
Aug. 17, 2020
Apr. 02, 2020
Mar. 27, 2020
Feb. 07, 2020
Jan. 30, 2020
May 31, 2019
Dec. 31, 2020
Dec. 31, 2019
May 04, 2017
Cash balance                 $ 1,928,804    
Restricted cash                 1,250,336 $ 336  
Working capital deficit                 $ 12,281,398    
Debt instrument interest rate                 2.50%   8.00%
Debt instrument monthly interest and principal payments             $ 1,180 $ 585      
PPP Loan [Member]                      
Proceeds from loan $ 2,000,000       $ 2,100,000            
Debt instrument interest rate         1.00%            
Debt instrument maturity date         Apr. 30, 2022            
Debt instrument monthly interest and principal payments         $ 119,000            
Convertible Preferred Stock: Series 2 [Member]                      
Preferred stock, shares outstanding                 787  
Series 2 Preferred Stock [Member]                      
Warrant to purchase shares of common stock     134,000                
Shares issued during the period new issues     $ 28,060                
Preferred stock, shares outstanding                 787    
Securities Purchase Agreement [Member] | Convertible Preferred Stock: Series 2 [Member] | Common Stock [Member]                      
Preferrred stock conversion           1,426,849          
Securities Purchase Agreement [Member] | Convertible Preferred Stock: Series 2 [Member] | Maximum [Member]                      
Shares issued during the period new issues, shares           1,500          
Shares issued during the period new issues           $ 1,500,000          
Shares issuing period description           The transaction occurred in two closings, the first of which, for 1,000 shares, occurred in mid-February 2020, and the second of which, for 500 shares, occurred in March 2020.          
Sonnet BioTherapeutics, Inc [Member]                      
Proceeds from merger       $ 6,000,000              
Warrant to purchase shares of common stock       186,161              
Price per share       $ 0.01              
Warrant issued upon merger description       Amergent received proceeds from Sonnet of $6,000,000 as well as a warrant to purchase 2% of the outstanding common shares of Sonnet (186,161 shares) for $0.01 per share ("Merger Consideration").              
Sale of stock, number of shares   100